Apricus Biosciences (APRI) Gets Israeli Patent NoA for PE Treatment Cream

Apricus Biosciences, Inc. (Nasdaq: APRI) reports that the Israeli Patent Office recently issued a Notice of Allowance to grant a patent for the Company's development of a topical cream utilizing vasoactive prostaglandin E to treat premature ejaculation ("PE"). When issued, the patent, entitled, "Compositions and Methods for the Treatment of Premature Ejaculation," will provide Israeli patent protection until March 2024. It is one in a series of issued patents and pending applications that Apricus Bio owns in the male sexual dysfunction field utilizing its proprietary NexACT® technology, which includes its Vitaros® product to treat erectile dysfunction ("ED"), among others in research and development.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Sky Quarry names Heidi Bowman as CFO
• BJ's Wholesale Club plans new location in Tyler, Texas
• Brightline Interactive begins trading on Nasdaq under ticker BTLN